Summary: evaluation of the evidence on the HeartMate II® and HeartWare® ventricular assist devices for the treatment of chronic end-stage heart failure
Québec; INESSS; Sept. 2012.
Non-conventional
in English
| BRISA/RedTESA
| ID: biblio-849294
Responsible library:
BR1.1
ABSTRACT
CONTEXT Heart failure is a complex syndrome that arises when the heart is incapable of pumping enough blood to respond to the metabolic needs of the body. Heart failure is often caused by defective contraction and relaxation of the myocardium, accompanied by elevated cardiac filling pressure. It represents the final stage of a number of cardiovascular diseases. Characterized by limitation in activities of daily living and progressive exhaustion at rest, heart failure is a disabling and life-threatening condition. Severe heart failure, defined as class IV using the functional classification scheme of the New York Heart Association (NYHA), is associated with a 1-year mortality of about 50%. Heart failure is a major public health problem, associated with high rates of morbidity and mortality. It is estimated that more than 80,000 people are affected in Quebec, and the incidence of heart failure is expected to increase as a result of ageing of the population. More than 75% of patients suffering from heart failure in
Full text:
Available
Collection:
Tematic databases
Health context:
6_ODS3_enfermedades_notrasmisibles
Health subject:
6_cardiovascular_diseases
/
6_other_circulatory_diseases
Database:
BRISA/RedTESA
Main topic:
Heart-Assist Devices
/
Heart Failure
Type of study:
Evaluation study
/
Health technology assessment
Demographic groups:
Humans
Language:
English
Year:
2012
Document type:
Non-conventional
Similar
MEDLINE
...
LILACS
LIS